Loading…
Employees: 1,712
Size Contec Medical Systems (300869.SZ) is a China Health Care company (Medical Specialties) with a market value of $600M, the 3422nd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥9.96 on 6 Nov 2026.
Performance Over six months the shares fell 22.9%, against -13.5% for the median peer and -16.4% for the China market (cap-weighted) — 7th lowest of 20 in its peer set.
Growth Revenue fell 2.5% over the last twelve months (peer median +10.2%); the operating margin is -16.1% (peer median 8.5%).
Valuation It trades at 6.3× enterprise value to sales against a peer median of 4.3× (6th most expensive of 19).
Price implies For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is -20%, so the hurdle is +37 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 13.4 points below its cost of capital (6.9% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥478M | CN¥464M | CN¥476M | CN¥737M | CN¥706M |
| Revenue growth | — | -2% | -36% | +5% | — |
| Gross profit | CN¥212M | CN¥210M | CN¥222M | CN¥408M | CN¥321M |
| EBITDA | n/a | -CN¥26.0M | -CN¥89.5M | CN¥137M | CN¥123M |
| Net income | -CN¥91.1M | -CN¥24.4M | -CN¥77.9M | CN¥166M | CN¥196M |
| Free cash flow | CN¥71.1M | CN¥25.1M | CN¥126M | CN¥258M | CN¥44.3M |
| Capital expenditure | CN¥23.5M | CN¥49.5M | CN¥54.5M | CN¥30.7M | CN¥81.4M |
| Total debt | CN¥810M | CN¥967M | CN¥787M | CN¥1.05B | CN¥1.58B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300869.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.4% | -3.3% | 6th lowest of 20 |
| 6-month return | -22.9% | -13.5% | 7th lowest of 20 |
| Distance from 52-week high | -45.0% | -34.3% | 6th lowest of 20 |
| Revenue growth (TTM) | -2.5% | +10.2% | 6th lowest of 20 |
| Operating margin | -16.1% | 8.5% | 4th lowest of 20 |
| EV / Sales | 6.3× | 4.3× | 6th most expensive of 19 |
| Growth the price implies (Req g, 7 yrs) | 17.3% | 7.4% | 4th most demanding of 12 |
| Growth delivered (Del g) | -19.8% | +6.7% | lowest of 12 |
| Hurdle (Req g minus delivered) | +37.1 pp | +0.5 pp | most demanding of 12 |
| ROIC minus cost of capital | -13.4 pp | +0.4 pp | 4th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Contec Medical Systems 300869.SZ | China | $600M | -23% | -2% | -16% | 6.3× | 17.3% | -19.8% |
| Medistim MEDI.OL | Norway | $601M | +30% | +19% | 29% | 6.8× | -1.8% | +14.5% |
| Nanosonics NAN.AX | Australia | $599M | -13% | +3% | 7% | 3.6× | 34.4% | +6.7% |
| Wuhan Huakang Century Clean Technology 301235.SZ | China | $603M | -42% | +28% | 7% | 1.7× | n/a | n/a |
| Ningbo David Medical Device 300314.SZ | China | $607M | +22% | +19% | 11% | 5.6× | n/a | n/a |
| Hangzhou AGS MedTech 688581.SS | China | $617M | -16% | -18% | 33% | 4.0× | 1.7% | +27.8% |
| Tactile Systems Technology TCMD | United States | $583M | +1% | +14% | 9% | 1.5× | 7.8% | +12.0% |
| Zhejiang Gongdong Medical Technology 605369.SS | China | $581M | -10% | +6% | 9% | 2.8× | 11.6% | +6.5% |
| Guangdong Hybribio Biotech 300639.SZ | China | $568M | -5% | -7% | 4% | 4.5× | 2.7% | -13.2% |
| Xvivo Perfusion XVIVO.ST | Sweden | $635M | -29% | +18% | 12% | 6.3× | 35.7% | +35.2% |
| Myriad Genetics MYGN | United States | $566M | +38% | -3% | -11% | 0.8× | n/a | n/a |
| Sahajanand Medical Technologies SMT.NS | India | $566M | n/a | n/a | n/a | n/a | n/a | n/a |
| SunMax Biotechnology 4728.TWO | Taiwan | $643M | +1% | +12% | 50% | 9.4× | -0.7% | +18.8% |
| Anbio Biotechnology NNNN | United States | $560M | -85% | +10% | 67% | n/a | n/a | n/a |
| Zhejiang Orient Gene Biotech 688298.SS | China | $559M | -17% | +18% | -60% | 2.0× | n/a | n/a |
| Cowealth Medical China 603122.SS | China | $648M | -28% | -18% | -5% | 6.8× | n/a | n/a |
| MedicalSystem Biotechnology 300439.SZ | China | $556M | -4% | +14% | 2% | 1.7× | 7.4% | -7.8% |
| Sight Sciences SGHT | United States | $555M | -14% | +9% | -33% | 6.2× | n/a | n/a |
| Anteris Technologies Global AVR | United States | $555M | -14% | -10% | -4,738% | 134.2× | n/a | n/a |
| Nanjing Vishee Medical Technology 688580.SS | China | $550M | -40% | +7% | 24% | 6.0× | 22.3% | +4.2% |
| AK Medical 1789.HK | Hong Kong | $664M | -26% | +16% | 26% | 2.2× | -11.4% | +6.7% |